TABLE 3.
Risk of renal and female breast cancer after a primary thyroid cancer, stratified by histology of thyroid cancer
| Cancer | 2–11 months
|
12–59 months
|
60–119 months
|
120+ months
|
Total
|
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. observed cases |
SIR (95% CI) | No. observed cases |
SIR (95% CI) | No. observed cases |
SIR (95% CI) | No. observed cases |
SIR (95% CI) | No. observed cases |
SIR | |
| Renal | 16 | 3.12 (1.78–5.06)* | 47 | 2.21 (1.63–2.94)* | 43 | 2.03 (1.47–2.74)* | 100 | 2.13 (1.73–2.59)* | 206 | 2.18 (1.89–2.5)* |
| Papillary | 12 | 3.17 (1.64–5.55)* | 40 | 2.50 (1.79–3.41)* | 29 | 1.82 (1.22–2.62)* | 74 | 2.08 (1.63–2.61)* | 155 | 2.17 (1.85–2.54) |
| Follicular | 3 | 5.48 (1.13–16.02)* | 3 | 1.27 (0.26–3.68) | 8 | 3.02 (1.3–5.95)* | 18 | 2.56 (1.52–4.04)* | 32 | 2.54 (1.73–3.58)* |
| Anaplastic | 0 | 0 (0–66.13) | 2 | 26.23 (3.18–94.75)* | 1 | 17.62 (0.45–98.2) | 0 | 0 (0–48.6) | 3 | 11.1 (2.29–32.45)* |
| Other | 1 | 7.72 (0.2–43.04) | 1 | 2.49 (0.06–13.9) | 2 | 5.55 (0.67–20.03) | 5 | 4.89 (1.59–11.4)* | 9 | 4.70 (2.15–8.92)* |
| Breast | 56 | 1.08 (0.82–1.4) | 254 | 1.18 (1.04–1.33)* | 254 | 1.19 (1.05–1.35)* | 449 | 1.02(0.92–1.12) | 1008 | 1.10 (1.03–1.17)* |
| Papillary | 50 | 1.25 (0.93–1.65) | 202 | 1.20 (1.04–1.38)* | 200 | 1.21 (1.04–1.38)* | 339 | 1.0 (0.89–1.11) | 791 | 1.11 (1.03–1.19)* |
Includes risks associated with only the most common histologies of thyroid cancer and any other thyroid histologic groups with significantly elevated SIRs. The SPTC tumors were divided into the following groups: (1) papillary thyroid cancer, (2) follicular cancer, (3) Hürthle cell cancer, (4) anaplastic cancer, (5) medullary thyroid cancer, (6) thyroid lymphoma, and (7) other, including carcinomas NOS, sarcomas, and squamous cell and neuroendocrine tumors
*
P <0.05